Navigation Links
Regulus Announces Addition to NASDAQ Biotechnology Index
Date:12/23/2013

LA JOLLA, Calif., Dec. 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 23, 2013. 

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB), which also meet other eligibility criteria. To be eligible for inclusion on this Index, companies must, among other things, initially have a minimum market capitalization of $200 million and a minimum average daily trading volume of 100,000 shares. The securities on this Index are evaluated semi-annually and serve as the basis for the iShares NASDAQ Biotechnology Index Fund (NASDAQ: IBB). For more information about the NASDAQ Biotechnology Index, please visit www.nasdaq.com.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi.  In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform. 

For more information, please visit http://www.regulusrx.com

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact: 
Amy Conrad
Director, Investor Relations and Corporate Communications
aconrad@regulusrx.com
858-202-6321
 
Media:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526


'/>"/>
SOURCE Regulus
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
2. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
3. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
4. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
5. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
6. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
7. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
8. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
9. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
10. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
11. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... Move from on one drop zone to the next using Colorize's dynamic moving camera. ... any project. This package includes a 3D slideshow environment with 1 to 5 focus ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
Breaking Medicine News(10 mins):